11/02/2016 18:56:46 Cookie Policy +44 (0) 207 0700 961 Free Membership Login

You’ve just added your first Follow! This is a brand new feature that will be at the core of several new tools and personalized information feeds that are coming soon.

You can see your current Follow list as a Monitor list here.

Please continue to add stocks to your Follow list so that when the new tools and feeds roll out, you’ll immediately get to make use of them! We will alert early adopters of the Follow list to these new features first.

Ekf Diagnostics Share Price (EKF)

Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.375p +3.75% 10.375p 10.00p 10.75p 11.00p 10.75p 10.75p 853,250 16:35:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) RN NRN
Health Care Equipment & Services 40.1 -4.0 -1.5 - 43.79

Ekf Diagnostics (EKF) Latest News

More Ekf Diagnostics News
Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Share Charts

1 Year Ekf Diagnostics Chart

1 Year Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics (EKF) Top Chat Posts

totaleclipse: Just to put in a tiny bit more information I heard that Selah sales people were being paid very high commissions per test to incentivize them. Like half! That's kind of excessive dont you think? If the reimbursers discovered that bit of information I would guess they would be less than happy as it suggests the margins are very wide and maybe the reason for the cut. >>Bigman. You spotted a good point. If we focus on the next driver for the EKF share price- i.e. the 6 months results, the sales will be enhanced by just the $0.5m you calculate for April and a further $1.5m for May and June- not sure if that is going to reignite the shares to recover their upward path. Anyone have any views on the 6 month numbers?
kestelmill: My hunch is this: -RZ sees this company as his next vehicle -RZ strategy will be as per his normal strategy - become major global Dx player via acquisition -RZ is fairly well aligned with DE/JB on strategy -Hence when DE/JB were challenged by major shareholders they saw RZ chairmanship as a good fall back option -They now have carte blanche to progress, at least for the time being. A bit like when a football club appoints a new manager - they've got a reasonable period to succeed. -Major shareholders will realise this and if it doesn't fit with their investment approach (risk, etc) they will bail out. This is happening now hence share price going down. -I wouldn't be surprised if RZ becomes CEO. It depends on his relationship with JB and how many shares he buys. -All depends on RZ now. Not such a bad horse to back but share price likely to go down before it recovers.
cisk: all, tbh I would expect the likes of Baines et al to be buying shares in the market at the current level. If they can't announce sales etc then thats the only option to shore up confidence. Assuming they could of course... I'm thoroughly disappointed in this whole episode - after hearing them discuss the tech, pipeline and opportunities at length many times I'm seriously surprised we're where we are. The much-trumpeted sales to Mexico for example have not been announced. Nor do I hold out hope of RZ coming to the rescue at a price anywhere near what we would find appetising. He didn't make a fortune by being generous to shareholders of companies he wants to acquire. Wan, I know you thought 10p was wide of the mark, but if RZ spots an opportunity to buy the whole lot, spin off the molecular division on nasdaq in 6 months and develop the diagnostic side, he'll take it and pay the minimum to do so. And the institutions that bought around 40p if memory serves would probably be glad to get this company off their books at 10p as it's unlikely they could shift any serious volume of stock without collapsing the share price even more from current levels. what the company is actually worth is anyone's guess. Probably what RZ is prepared to pay as so far he looks like the only person who might buy the company.
cisk: Morning Wan Agree - Mgt will be judged on next month's update - but as we both know, it takes a long time to gain any sort of traction in diagnostics - in fact anything healthcare related - as my small holding in Deltex will attest to! Very interesting news re: Alere; given the already strong relationship between them and Ron's shareholding in both companies it would not be a surprise. However I'm in it for the long term and believe that the share price can be at multiples of its current level, so personally I wouldn't want to see them taken over at a price anywhere near the current share price. Hopefully patience will be my biggest ally...
cisk: Inter, talk is cheap and these guys have been paid handsomely for their efforts - or lack of. Anyone can apologise - indeed I've witnessed this first hand several times from these guys; it will take more than talk to get this share price up.
interstellar: Yes Bigman- my point entirely. No one objects (least of all me) to competitive salaries but they come with responsibility to deliver and this is outrageous non-performance. Way too cozy. The bottom line would look healthier without these expenses and it is us shareholders that are paying for it. Personally, with no positive evidence to the contrary, I think the year end is going to be awful. There has been little or no improvement in the exchange rate (if anything the pound is stronger) especially against the rouble meaning that accounts are going to take a hit again. There has been no announcement of big contracts won as heralded at the half way stage and here we are in week 44. A potential suitor has performed extensive due diligence and walked away from the negotiation table (not a good sign when the company has lifted its skirts to show all) and the share price has taken a big hit. And the institutional investors are losing patience. Brace yourselves.
interstellar: Well Wan. You should be a very successful investor with such a strategy since a general consensus is populations are growing everywhere (except perhaps Germany and a few other developed territories). Sorry I am feeling grumpy. As I write the share price is down to 17pence (albeit on a small sell) and there is no word from the company on the situation they have plunged us in. David Evans said words to the effect that they would keep us informed of progress against tenders submitted when they were able to do so. No information can only mean no progress.
interstellar: Quite Cisk. But what's the Molecular Business worth. With the company valued at 90 odd million overall as I write this then the remainder must be worth around 20 million- or so the market thinks since the share price hasn't reacted at all. I always thought it a mistake for EKF to start moving way from POC as this kind of confirms it. Does anyone else get the feeling that DE is a bit- how should I put it- upset by the position he finds himself in now???
kestelmill: Can someone help me understand this. The share price is pretty much as low as it has ever been. Therefore the shareholders who are asking for the company to be broken up are going to lose money if they sell as of today. So why not: i) sell or offload the bad bits, ii) give the company more time to grow. It's not as if Julian Baines and David Evans don't have the track record. I don't really understand what the major shareholders are hoping for if they are considering selling off the best part of the business.
andrewbaker: I think that the stock overhang may now be in the past, or close to in the past, and the true value of the company's business may now be better appreciated through its share price. The recent news is good, and hopefully so will future news; such that the share price may in future properly reflect the potential that is there. This is one smaller company that I hold, and will continue so to do for the foreseeable future.

Ekf Diagnostics (EKF) Latest Trade

Ekf Diagnostics Most Recent Trade

Trade Type Trade Size Trade Price Trade Date Trade Time Currency
O 350,000 10.10 11 Feb 2016 16:29:56 GBX
Ekf Diagnostics share price data is direct from the London Stock Exchange

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20160211 18:56:46